Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21N.ClH |
Molecular Weight | 311.848 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CCC=C1C2=C(C=CC=C2)C=CC3=C1C=CC=C3
InChI
InChIKey=VXEAYBOGHINOKW-UHFFFAOYSA-N
InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H21N |
Molecular Weight | 275.3874 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/slideshow/flexeril-cyclobenzaprine-muscle-relaxants-1266 | http://www.rxlist.com/flexeril-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/26926618 | https://www.ncbi.nlm.nih.gov/pubmed/26668287
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/slideshow/flexeril-cyclobenzaprine-muscle-relaxants-1266 | http://www.rxlist.com/flexeril-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/26926618 | https://www.ncbi.nlm.nih.gov/pubmed/26668287
Cyclobenzaprine is a centrally-acting muscle relaxant which boosts levels of norepinephrine and binds to serotonin receptors in the brain to reduce spasm. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Drowsiness, fatigue and sedation (up to 40%) is the most common side effect of Cyclobenzaprine. It may have life-threatening interactions with monoamine oxidase (MAO) inhibitors. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093870 |
|||
Target ID: CHEMBL340 |
|||
Target ID: CHEMBL3356 |
|||
Target ID: CHEMBL289 |
|||
Target ID: CHEMBL3257 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14681337 |
3.1 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | CYCLOBENZAPRINE HYDROCHLORIDE Approved UseDrug is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Launch Date1988 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19243711 |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CYCLOBENZAPRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
354.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19243711 |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CYCLOBENZAPRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19243711 |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
CYCLOBENZAPRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: Page: p.282 |
healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: Page: p.282 |
Disc. AE: Lethargy, Slurred speech... AEs leading to discontinuation/dose reduction: Lethargy Sources: Page: p.282Slurred speech Sinus tachycardia |
600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: Page: p.283 |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: F Population Size: 1 Sources: Page: p.283 |
Disc. AE: Sinus tachycardia, Confusion... AEs leading to discontinuation/dose reduction: Sinus tachycardia Sources: Page: p.283Confusion Drowsiness Agitation Visual hallucinations |
10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: Page: p.1068 |
unhealthy, 41.5 n = 249 Health Status: unhealthy Condition: Muscle spasm Age Group: 41.5 Sex: M+F Population Size: 249 Sources: Page: p.1068 |
Disc. AE: Somnolence... AEs leading to discontinuation/dose reduction: Somnolence (5.2%) Sources: Page: p.1068 |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Muscle spasm Sources: Page: p.1 |
Disc. AE: Serotonin syndrome, Cardiovascular disorder NOS... AEs leading to discontinuation/dose reduction: Serotonin syndrome (grade 4) Sources: Page: p.1Cardiovascular disorder NOS CNS depression |
15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Other AEs: Tachycardia, Dry mouth... Other AEs: Tachycardia (below serious, 1 patient) Sources: Dry mouth (below serious, 6 patients) Toothache (below serious, 1 patient) Rhinitis (below serious, 1 patient) Dizziness (below serious, 1 patient) Dysgeusia (below serious, 1 patient) Anxiety (below serious, 1 patient) Disruptive mood dysregulation disorder (below serious, 1 patient) Sleep disorder (below serious, 1 patient) Somnolence (below serious, 18 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Lethargy | Disc. AE | 900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: Page: p.282 |
healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: Page: p.282 |
Sinus tachycardia | Disc. AE | 900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: Page: p.282 |
healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: Page: p.282 |
Slurred speech | Disc. AE | 900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: Page: p.282 |
healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: Page: p.282 |
Agitation | Disc. AE | 600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: Page: p.283 |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: F Population Size: 1 Sources: Page: p.283 |
Confusion | Disc. AE | 600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: Page: p.283 |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: F Population Size: 1 Sources: Page: p.283 |
Drowsiness | Disc. AE | 600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: Page: p.283 |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: F Population Size: 1 Sources: Page: p.283 |
Sinus tachycardia | Disc. AE | 600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: Page: p.283 |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: F Population Size: 1 Sources: Page: p.283 |
Visual hallucinations | Disc. AE | 600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: Page: p.283 |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: F Population Size: 1 Sources: Page: p.283 |
Somnolence | 5.2% Disc. AE |
10 mg 3 times / day multiple, oral Recommended Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: Page: p.1068 |
unhealthy, 41.5 n = 249 Health Status: unhealthy Condition: Muscle spasm Age Group: 41.5 Sex: M+F Population Size: 249 Sources: Page: p.1068 |
CNS depression | Disc. AE | 30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Muscle spasm Sources: Page: p.1 |
Cardiovascular disorder NOS | Disc. AE | 30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Muscle spasm Sources: Page: p.1 |
Serotonin syndrome | grade 4 Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Muscle spasm Sources: Page: p.1 |
Anxiety | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Disruptive mood dysregulation disorder | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Dizziness | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Dysgeusia | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Rhinitis | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Sleep disorder | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Tachycardia | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Toothache | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Somnolence | below serious, 18 patients | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
Dry mouth | below serious, 6 patients | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 90 Health Status: unhealthy Condition: Cervical and/or Lower Back Pain Population Size: 90 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. | 2004 Aug |
|
Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. | 2004 Feb 15 |
|
Human liver aldehyde oxidase: inhibition by 239 drugs. | 2004 Jan |
|
A randomized clinical trial comparing chiropractic adjustments to muscle relaxants for subacute low back pain. | 2004 Jul-Aug |
|
Emphysematous cystitis: an unusual disease of the Genito-Urinary system suspected on imaging. | 2004 Oct 5 |
|
Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. | 2004 Sep |
|
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. | 2004 Sep |
|
Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets. | 2004 Sep-Oct |
|
Usage of pain medications during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). | 2005 Fall |
|
Interactions of cyclobenzaprine and tricyclic antidepressants. | 2005 Jan |
|
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. | 2005 Jan |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Biology and therapy of fibromyalgia. New therapies in fibromyalgia. | 2006 |
|
Efficacy and safety of acupuncture for the treatment of non-specific acute low back pain: a randomised controlled multicentre trial protocol [ISRCTN65814467]. | 2006 Apr 21 |
|
Antidepressants in the treatment of fibromyalgia. | 2006 Dec |
|
Transient synovitis of the hip in an adult. | 2006 Feb |
|
Inappropriate prescribing in an older ED population. | 2007 Sep |
|
Characteristics and healthcare costs of patients with fibromyalgia syndrome. | 2007 Sep |
|
Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. | 2008 |
|
Choosing a skeletal muscle relaxant. | 2008 Aug 1 |
|
Treatment options and patient perspectives in the management of fibromyalgia: future trends. | 2008 Dec |
|
Rasagiline in treatment of Parkinson's disease. | 2008 Feb |
|
Skeletal muscle relaxants. | 2008 Feb |
|
Lower facial contouring with botulinum toxin type A. | 2008 Nov |
|
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. | 2008 Nov 30 |
|
Elderly patient refractory to multiple pain medications successfully treated with integrative East-West medicine. | 2008 Nov 30 |
|
Neuralgic amyotrophy associated with antibiotic therapy. | 2008 Sep |
|
Torticollis under cyclobenzaprine. | 2009 |
|
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology. | 2009 |
|
Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. | 2009 |
|
Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study. | 2009 |
|
Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability. | 2009 Apr |
|
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. | 2009 Apr 28 |
|
A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. | 2009 Jan |
|
Rhabdomyolysis associated with the nutritional supplement Hydroxycut. | 2009 Jan 15 |
|
Cyclobenzaprine for the treatment of myofascial pain in adults. | 2009 Jul 8 |
|
Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity? | 2009 May |
|
Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design. | 2009 May |
|
Standardized natural product cannabis in pain management and observations at a Canadian compassion society: a case report. | 2009 May 18 |
|
Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. | 2009 May-Jun |
|
Fibromyalgia and myofascial pain syndrome-a dilemma. | 2009 Oct |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Electroencephalographic correlates of Chronic Fatigue Syndrome. | 2009 Oct 6 |
|
Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study. | 2009 Oct 7 |
|
Menstrual-related nummular headache. | 2010 Apr |
|
Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis. | 2010 Jul |
|
Pharmacologic management of chronic pain. | 2010 Jun |
|
Case files of the California poison control system, San Francisco division: blue thunder ingestion: methanol, nitromethane, and elevated creatinine. | 2010 Mar |
|
Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry. | 2010 Mar |
|
Pharmacokinetic profile of once-daily cyclobenzaprine extended-release. | 2010 Nov |
Patents
Sample Use Guides
5 mg three times a day. Based on individual patient response, the dose may be increased to either 7.5 mg or 10 mg three times a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6835493
The iontaphoretic application of Cyclobenzaprine (CBZ) caused, in all cases, a decrease in discharge rate. This slowing was invariably attended by a marked decrease in action potential amplitude however, and was therefore considered likely to be a local anesthetic effect, even at 5 nA. On the other hand, when CBZ was infused into the chamber to a concentration equivalent to 1 mg/kg for the whole animal, assuming distribution in all extracellular water, all cells responded and no local anesthetic effects were evident. The six cells with initial discharge rates between 2 and 10 Hz decreased firing with CBZ, whereas the four cells with initial rates between 0.5 and 1.5 Hz increased their rates with CBZ.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:32:12 GMT 2023
by
admin
on
Fri Dec 15 15:32:12 GMT 2023
|
Record UNII |
0VE05JYS2P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
22576
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
SUB13514MIG
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL669
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
m3976
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
1154503
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
100000079509
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
0VE05JYS2P
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
0VE05JYS2P
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
169900
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
6202-23-9
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
DTXSID2045105
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
DBSALT000479
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
228-264-4
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
173379
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
C47465
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
78206
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
3997
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | |||
|
52101
Created by
admin on Fri Dec 15 15:32:12 GMT 2023 , Edited by admin on Fri Dec 15 15:32:12 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|